[go: up one dir, main page]

MX2017004196A - Anticuerpos contra ticagrelor y metodos de uso. - Google Patents

Anticuerpos contra ticagrelor y metodos de uso.

Info

Publication number
MX2017004196A
MX2017004196A MX2017004196A MX2017004196A MX2017004196A MX 2017004196 A MX2017004196 A MX 2017004196A MX 2017004196 A MX2017004196 A MX 2017004196A MX 2017004196 A MX2017004196 A MX 2017004196A MX 2017004196 A MX2017004196 A MX 2017004196A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
ticagrelor
description
antigen
Prior art date
Application number
MX2017004196A
Other languages
English (en)
Other versions
MX389103B (es
Inventor
Buchanan Andrew
Nylander Sven
Penney Mark
Newton Philip
Keyes Feenagh
Inghardt Tord
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2017004196A publication Critical patent/MX2017004196A/es
Publication of MX389103B publication Critical patent/MX389103B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La descripción proporciona en general anticuerpos y fragmentos de anticuerpos de unión a antígenos que se unen a ticagrelor y metabolitos de ticagrelor. La descripción proporciona también composiciones que comprenden los anticuerpos, moléculas de ácidos nucleicos que codifican los anticuerpos, métodos de tratar a un paciente, que comprende administrar los anticuerpos y métodos de producir y utilizar los anticuerpos.
MX2017004196A 2014-10-01 2015-09-30 Anticuerpos contra ticagrelor y métodos de uso. MX389103B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462058458P 2014-10-01 2014-10-01
US201562114931P 2015-02-11 2015-02-11
PCT/EP2015/072606 WO2016050867A1 (en) 2014-10-01 2015-09-30 Antibodies to ticagrelor and methods of use

Publications (2)

Publication Number Publication Date
MX2017004196A true MX2017004196A (es) 2017-07-19
MX389103B MX389103B (es) 2025-03-20

Family

ID=54238444

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004196A MX389103B (es) 2014-10-01 2015-09-30 Anticuerpos contra ticagrelor y métodos de uso.
MX2022000242A MX2022000242A (es) 2014-10-01 2017-03-30 Anticuerpos contra ticagrelor y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000242A MX2022000242A (es) 2014-10-01 2017-03-30 Anticuerpos contra ticagrelor y metodos de uso.

Country Status (12)

Country Link
US (5) US9982061B2 (es)
EP (1) EP3201235A1 (es)
JP (2) JP6799530B2 (es)
KR (2) KR102767586B1 (es)
CN (2) CN106715473B (es)
AU (2) AU2015326869B2 (es)
CA (1) CA2963166C (es)
MX (2) MX389103B (es)
NZ (1) NZ730247A (es)
RU (1) RU2021125449A (es)
TW (2) TWI707870B (es)
WO (1) WO2016050867A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016050867A1 (en) * 2014-10-01 2016-04-07 Medimmune Limited Antibodies to ticagrelor and methods of use
WO2018212556A1 (en) * 2017-05-16 2018-11-22 Cj Healthcare Corporation A method for purifying an antibody or an antibody fragment thereof using affinity chromatography
CN107976497B (zh) * 2017-11-23 2020-11-10 重庆华邦制药有限公司 替格瑞洛中间体1的合成反应程度测定方法及应用
WO2020061465A1 (en) * 2018-09-20 2020-03-26 Phasebio Pharmaceuticals, Inc. Methods of reversing ticagrelor activity
CN114432315B (zh) * 2020-11-05 2025-02-11 华东师范大学 一种预防、治疗疼痛的化合物及其应用
WO2022240754A2 (en) * 2021-05-10 2022-11-17 Phasebio Pharmaceuticals, Inc. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
WO2026019858A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TW530058B (en) 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
JP2004501642A (ja) 2000-06-28 2004-01-22 グライコフィ，　インコーポレイテッド 改変された糖タンパク質を生成するための方法
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2482448C (en) 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
US7378110B2 (en) 2002-12-17 2008-05-27 Med Immune Vaccines, Inc. High pressure spray-dry of bioactive materials
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US7884264B2 (en) 2006-01-17 2011-02-08 Biolex Therapeutics, Inc. Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
MX2009001620A (es) * 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
RU2013154741A (ru) 2011-06-01 2015-07-20 Астразенека Аб Новый сокристалл тикагрелора
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US10363040B2 (en) 2014-05-02 2019-07-30 W. L. Gore & Associates, Inc. Anastomosis devices
WO2016050867A1 (en) 2014-10-01 2016-04-07 Medimmune Limited Antibodies to ticagrelor and methods of use
JP7110199B2 (ja) 2016-12-23 2022-08-01 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体による処置法
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
WO2020061465A1 (en) 2018-09-20 2020-03-26 Phasebio Pharmaceuticals, Inc. Methods of reversing ticagrelor activity
WO2022240754A2 (en) 2021-05-10 2022-11-17 Phasebio Pharmaceuticals, Inc. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody

Also Published As

Publication number Publication date
US20190077882A1 (en) 2019-03-14
JP6799530B2 (ja) 2020-12-16
MX389103B (es) 2025-03-20
JP2017535252A (ja) 2017-11-30
RU2021125449A (ru) 2021-09-16
KR102767586B1 (ko) 2025-02-17
US11773186B2 (en) 2023-10-03
US20240101712A1 (en) 2024-03-28
US10487154B2 (en) 2019-11-26
JP7027502B2 (ja) 2022-03-01
CA2963166C (en) 2023-10-03
US9982061B2 (en) 2018-05-29
TW201617370A (zh) 2016-05-16
MX2022000242A (es) 2022-02-03
KR20230153495A (ko) 2023-11-06
KR102594117B1 (ko) 2023-10-26
NZ730247A (en) 2022-11-25
TWI707870B (zh) 2020-10-21
RU2017114645A (ru) 2018-11-07
WO2016050867A1 (en) 2016-04-07
US20210371546A1 (en) 2021-12-02
CA2963166A1 (en) 2016-04-07
US20160130366A1 (en) 2016-05-12
RU2754468C2 (ru) 2021-09-02
TWI774071B (zh) 2022-08-11
CN106715473A (zh) 2017-05-24
CN106715473B (zh) 2021-11-23
US20180319897A1 (en) 2018-11-08
JP2021011485A (ja) 2021-02-04
CN113956361A (zh) 2022-01-21
KR20170061695A (ko) 2017-06-05
TW202104271A (zh) 2021-02-01
AU2015326869B2 (en) 2021-04-29
AU2015326869A1 (en) 2017-04-06
US10954308B2 (en) 2021-03-23
AU2021209207A1 (en) 2021-08-19
US12391768B2 (en) 2025-08-19
AU2021209207B2 (en) 2024-03-14
EP3201235A1 (en) 2017-08-09
CN113956361B (zh) 2025-06-17
RU2017114645A3 (es) 2019-05-07

Similar Documents

Publication Publication Date Title
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
EA201792613A1 (ru) Модуляторы cot и способы их применения
MX2018005551A (es) Anticuerpos que se unen especificamente a pd-1, y sus usos.
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
ECSP18033227A (es) Anticuerpos agonistas que se unen específicamente a CD40 humana y métodos de uso
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
CR20160347A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
CO2018000809A2 (es) Anticuerpos para cd40
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
ECSP13012859A (es) Anticuerpos del cea
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso